# Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

Source: https://onco.cc/trials/nct06607796/  
OnCo record `nct06607796` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Zhou Chengzhi, now recruiting.

## Summary

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy is a phase 3, randomised interventional study registered as NCT06607796 by Zhou Chengzhi, with a registry enrolment figure of 180 participants, started 2024-03-01 and due to reach its primary completion in 2026-12. Interventions recorded: Toluenesulfonamide (PTS) Intratumoral Injection. Conditions listed: Lung Cancer. Primary outcome: Objective response rate(ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed stage IV (AJCC 8th edition) driver gene negative non-small cell lung cancer；". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06607796
- Phase: 3
- Setting: A Multicenter Study of the Efficacy and Safety of Intratumoral Injection of Toluenesulfonamide (PTS) in Combination With or Without First-line Chemoimmunotherapy Based on Standard Treatment for Stage IV Driver Gene-negative Non-small Cell Lung Cancer
- Sponsor: Zhou Chengzhi
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06607796: https://clinicaltrials.gov/study/NCT06607796

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06607796.json